CervoMed’s Neflamapimod Secures the US FDA’s Orphan Drug Designation to Treat Frontotemporal Dementia
Shots:
- The US FDA has granted Orphan Drug Designation to neflamapimod for the treatment of frontotemporal dementia (FTD)
- Neflamapimod (40mg, oral, TID) is being studied under P-IIb (RewinD-LB) trial in early-stage DLB patients (n=159), with topline data planned in Dec 2024. Discussions are underway for a proof-of-principle study in FTD, with preparations for P-III trial in DLB set for mid-2025
- In preclinical studies, neflamapimod reversed synaptic dysfunction in the basal forebrain. It was well-tolerated in P-I & P-II with over 300 subjects. The P-IIa (AscenD-LB) study showed improved dementia severity, functional mobility & cognitive function
Ref: CervoMed | Image: CervoMed
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
